307 related articles for article (PubMed ID: 31427282)
21. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
22. Temozolomide in glioblastoma treatment: 15-year clinical experience and analysis of its efficacy.
Glavatskyi OY; Zemskova OV; Khmelnytskyi HV; Kardash KA; Shuba IM; Stuley VA
Exp Oncol; 2020 Jun; 42(2):148-156. PubMed ID: 32602292
[TBL] [Abstract][Full Text] [Related]
23. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.
Lieberman FS; Wang M; Robins HI; Tsien CI; Curran WJ; Werner-Wasik M; Smith RP; Schultz C; Hartford AC; Zhang P; Mehta MP
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):878-886. PubMed ID: 30496882
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
26. Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.
Balducci M; Fiorentino A; De Bonis P; Chiesa S; Mangiola A; Mattiucci GC; D'Agostino GR; Frascino V; Mantini G; Alitto AR; Colosimo C; Anile C; Valentini V
Strahlenther Onkol; 2013 Nov; 189(11):926-31. PubMed ID: 23974823
[TBL] [Abstract][Full Text] [Related]
27. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
Shawky H; Abo Hamar AH; Galal S; Zakaria F; El-Shorbagy D
J Egypt Natl Canc Inst; 2009 Jun; 21(2):107-19. PubMed ID: 21057562
[TBL] [Abstract][Full Text] [Related]
28. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
Kumthekar P; Grimm S; Chandler J; Mehta M; Marymont M; Levy R; Muro K; Helenowski I; McCarthy K; Fountas L; Raizer J
J Neurooncol; 2017 Jul; 133(3):589-594. PubMed ID: 28510787
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
31. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
[TBL] [Abstract][Full Text] [Related]
32. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
Lim M; Weller M; Idbaih A; Steinbach J; Finocchiaro G; Raval RR; Ansstas G; Baehring J; Taylor JW; Honnorat J; Petrecca K; De Vos F; Wick A; Sumrall A; Sahebjam S; Mellinghoff IK; Kinoshita M; Roberts M; Slepetis R; Warad D; Leung D; Lee M; Reardon DA; Omuro A
Neuro Oncol; 2022 Nov; 24(11):1935-1949. PubMed ID: 35511454
[TBL] [Abstract][Full Text] [Related]
33. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
Lee A; Malakhov N; Sheth N; Wang A; Han P; Schreiber D
Clin Neurol Neurosurg; 2018 Jul; 170():127-131. PubMed ID: 29777945
[TBL] [Abstract][Full Text] [Related]
34. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
35. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
[TBL] [Abstract][Full Text] [Related]
36. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
37. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
[TBL] [Abstract][Full Text] [Related]
38. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
39. Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study.
Wei KC; Hsu PW; Tsai HC; Lin YJ; Chen KT; Toh CH; Huang HL; Jung SM; Tseng CK; Ke YX
Sci Rep; 2021 Dec; 11(1):24067. PubMed ID: 34911992
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Mertsoylu H; Tufan K
J Neurooncol; 2018 Sep; 139(2):411-419. PubMed ID: 29696530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]